Literature DB >> 19744964

Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes.

M Di Filippo1, V M Anderson, D R Altmann, J K Swanton, G T Plant, A J Thompson, D H Miller.   

Abstract

BACKGROUND: Conventional MRI lesion measures modestly predict long term disability in some clinically isolated syndrome (CIS) studies. Brain atrophy suggests neuroaxonal loss in multiple sclerosis (MS) with the potential to reflect disease progression to a greater extent than lesion measures.
OBJECTIVE: To investigate whether brain atrophy and lesion load, during the first year in patients presenting with CIS, independently predict clinical outcome (development of MS and disability at 6 years).
METHODS: 99 patients presenting with CIS were included in the study. T1 gadolinium enhanced and T2 weighted brain MRI was acquired at baseline and approximately 1 year later. Percentage brain atrophy rate between baseline and follow-up scans was analysed using SIENA.
RESULTS: Mean annual brain atrophy rates were -0.38% for all patients, -0.50% in patients who had developed MS at 6 years and -0.26% in those who had not. Brain atrophy rate (p = 0.005) and baseline T2 lesion load (p<0.001) were independent predictors of clinically definite MS. While brain atrophy rate was a predictor of Expanded Disability Status Scale (EDSS) score in a univariate analysis, only 1 year T2 lesion load change (p = 0.007) and baseline gadolinium enhancing lesion number (p = 0.03) were independent predictors of EDSS score at the 6 year follow-up. T1 lesion load was the only MRI parameter which predicted Multiple Sclerosis Functional Composite score at the 6 year follow-up.
CONCLUSIONS: The findings confirm that brain atrophy occurs during the earliest phases of MS and suggest that 1 year longitudinal measures of MRI change, if considered together with baseline MRI variables, might help to predict clinical status 6 years after the first demyelinating event in CIS patients, better than measurements such as lesion or brain volumes on baseline MRI alone.

Entities:  

Mesh:

Year:  2009        PMID: 19744964     DOI: 10.1136/jnnp.2009.171769

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

Review 1.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

2.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

3.  Gadolinium-Enhanced Susceptibility-Weighted Imaging in Multiple Sclerosis: Optimizing the Recognition of Active Plaques for Different MR Imaging Sequences.

Authors:  L L F do Amaral; D C Fragoso; R H Nunes; I A Littig; A J da Rocha
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

4.  Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes.

Authors:  Maria José Magraner; Isabel Bosca; Maria Simó-Castelló; Gracian García-Martí; Angel Alberich-Bayarri; Francisco Coret; Jose C Alvarez-Cermeño; Luís Martí-Bonmatí; Luisa M Villar; Bonaventura Casanova
Journal:  Neuroradiology       Date:  2011-02-16       Impact factor: 2.804

5.  Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.

Authors:  Ellen M Mowry; Emmanuelle Waubant; Charles E McCulloch; Darin T Okuda; Alan A Evangelista; Robin R Lincoln; Pierre-Antoine Gourraud; Don Brenneman; Mary C Owen; Pamela Qualley; Monica Bucci; Stephen L Hauser; Daniel Pelletier
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

6.  The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Authors:  Douglas R Jeffery; Elisabetta Verdun Di Cantogno; Shannon Ritter; Daniela Piani Meier; Ernst-Wilhelm Radue; William Camu
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

Review 7.  The prognostic utility of MRI in clinically isolated syndrome: a literature review.

Authors:  C Odenthal; A Coulthard
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-15       Impact factor: 3.825

Review 8.  Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Authors:  Rebecca S Farber; Ilana K Sand
Journal:  Ther Adv Neurol Disord       Date:  2015-09       Impact factor: 6.570

9.  Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.

Authors:  Tomas Kalincik; Manuela Vaneckova; Michaela Tyblova; Jan Krasensky; Zdenek Seidl; Eva Havrdova; Dana Horakova
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

10.  Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.

Authors:  Sushmita Datta; Terrell D Staewen; Stacy S Cofield; Gary R Cutter; Fred D Lublin; Jerry S Wolinsky; Ponnada A Narayana
Journal:  Mult Scler Relat Disord       Date:  2015-01-17       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.